Curtiaud Anaïs, Iba Toshiaki, Angles-Cano Eduardo, Meziani Ferhat, Helms Julie
Faculté de Médecine, Service de Médecine Intensive-Réanimation, Université de Strasbourg (UNISTRA), Hôpitaux universitaires de Strasbourg, Nouvel Hôpital Civil, 1, place de l'Hôpital, Strasbourg, F-67091, cedex, France.
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine (RNM), FMTS, Strasbourg, France.
Ann Intensive Care. 2025 Jan 17;15(1):12. doi: 10.1186/s13613-025-01434-2.
Diagnosing coagulopathy in septic patients remains challenging in intensive care. Disseminated intravascular coagulation (DIC) indeed presents with complex pathophysiology, complicating timely diagnosis. Epidemiological data indicate a significant prevalence of DIC in septic patients, with mortality rates up to 60%. Despite advances, current biomarker-based diagnostic tools often fail to provide early and accurate detection. This review evaluates the utility and limitations of traditional and emerging biomarkers for diagnosing sepsis-induced coagulopathy (SIC) and DIC. We also assess the effectiveness of anticoagulant therapy guided by biomarker-based diagnostic criteria.
在重症监护中，诊断脓毒症患者的凝血病仍然具有挑战性。弥散性血管内凝血（DIC）的病理生理学确实很复杂，这使得及时诊断变得困难。流行病学数据表明，脓毒症患者中DIC的患病率很高，死亡率高达60%。尽管取得了进展，但目前基于生物标志物的诊断工具往往无法提供早期准确的检测。本文综述评估了传统和新兴生物标志物在诊断脓毒症诱导的凝血病（SIC）和DIC方面的效用和局限性。我们还评估了基于生物标志物诊断标准指导的抗凝治疗的有效性。
